2021
DOI: 10.1245/s10434-021-10657-z
|View full text |Cite
|
Sign up to set email alerts
|

The Changing Demographics and Treatment of Larynx Cancer

Abstract: A dominant narrative in the treatment of larynx cancer has been balancing effective oncologic therapy with the preservation of major laryngeal functions such as breathing, swallowing, and speech. The first total laryngectomy, described by Billroth in 1873, was able to maintain the airway, and, separated the pharynx from the trachea, allowing swallowing without aspiration. 1 With modern tracheoesophageal prostheses for speech, total laryngectomy provides an oncologically comprehensive operation that facilitates… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
2
1

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(3 citation statements)
references
References 9 publications
0
3
0
Order By: Relevance
“…Lymph node metastasis evaluation is one of the most informative data for the treatment planning of LSCC patients, with neck dissection being elective for earlystage disease, or in those patients with no evidence of lymph node metastasis in clinical evaluation (cN0). [13][14][15] However, some patients with glottic LSCC may have a tumor recurrence due to a non-diagnosed lymph node metastasis, impacting prognosis. 2,[16][17][18] Therefore, biomarkers capable of identifying prognostic and positive lymph node metastasis in glottic LSCC is essential for improving the risk classification of patients, and the choice of therapy modality.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Lymph node metastasis evaluation is one of the most informative data for the treatment planning of LSCC patients, with neck dissection being elective for earlystage disease, or in those patients with no evidence of lymph node metastasis in clinical evaluation (cN0). [13][14][15] However, some patients with glottic LSCC may have a tumor recurrence due to a non-diagnosed lymph node metastasis, impacting prognosis. 2,[16][17][18] Therefore, biomarkers capable of identifying prognostic and positive lymph node metastasis in glottic LSCC is essential for improving the risk classification of patients, and the choice of therapy modality.…”
Section: Discussionmentioning
confidence: 99%
“…Lymph node metastasis evaluation is one of the most informative data for the treatment planning of LSCC patients, with neck dissection being elective for early‐stage disease, or in those patients with no evidence of lymph node metastasis in clinical evaluation (cN0) 13–15 . However, some patients with glottic LSCC may have a tumor recurrence due to a non‐diagnosed lymph node metastasis, impacting prognosis 2,16–18 .…”
Section: Discussionmentioning
confidence: 99%
“…The occurrence of laryngeal cancers has increased by 12 % during the past 3 decades [ 3 ]. However, the 5-year survival rate of laryngeal cancer has not improved significantly in recent years despite the multimodal treatment [ 4 ].…”
Section: Introductionmentioning
confidence: 99%